

Hand, Foot and Mouth Disease R&D Pipeline Analysis Report, Q4 2020

https://marketpublishers.com/r/H74A0B1947EAEN.html

Date: October 2020

Pages: 61

Price: US\$ 1,699.00 (Single User License)

ID: H74A0B1947EAEN

Abstracts

Hand, Foot and Mouth Disease Pipeline Overview

The Q4 Hand, Foot and Mouth Disease pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Hand, Foot and Mouth Disease, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Hand, Foot and Mouth Disease Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Hand, Foot and Mouth Disease disease overview, Hand, Foot and Mouth Disease types, Hand, Foot and Mouth Disease symptoms, causes, and FDA/EMA approved treatment options.

Hand, Foot and Mouth Disease Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Hand, Foot and Mouth Disease indication. The report presents near-term and long-term pipeline development trends and potential insights.

Hand, Foot and Mouth Disease Company Trends and Insights
The report analyzes the development progress, current status, investments,
partnerships, and other developments of 9 companies. Business profiles and contact
details of the companies actively perusing Hand, Foot and Mouth Disease pipeline are
assessed.

Hand, Foot and Mouth Disease R&D Pipeline Development Phase Trends and Insights



From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Hand, Foot and Mouth Disease discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Hand, Foot and Mouth Disease companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Hand, Foot and Mouth Disease pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Hand, Foot and Mouth Disease Pipeline Market News and Developments during 2020 The Hand, Foot and Mouth Disease industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Hand, Foot and Mouth Disease Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and
their progress is included. New mechanisms of actions introduced during the year, route
of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

Hand, Foot and Mouth Disease pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new



molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and investment details of companies are included

9 companies are included including Adimmune Corp, Beijing Minhai Biotechnology Co Ltd, Changchun Bcht Biotechnology Co Ltd, Chongqing Zhifei Biological Products Co Ltd, CJ HealthCare Corp, Emergex Vaccines Ltd, Sentinext Therapeutics Sdn Bhd, Shanghai Zerun Biotechnology Co Ltd, Takeda Pharmaceutical Co Ltd,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Hand, Foot and Mouth Disease pipeline market

Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

Reasons to Buy

Drive pipeline research and commercial assessment

Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition opportunities

Develop new candidates based on most focused targets and mechanism of actions







Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. HAND, FOOT AND MOUTH DISEASE PIPELINE TRENDS AND INSIGHTS

- 2.1 Dominant Phase type of Hand, Foot and Mouth Disease Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Hand, Foot and Mouth Disease Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Hand, Foot and Mouth Disease pipeline
- 2.5 Active Companies Developing Hand, Foot and Mouth Disease pipeline

3. HAND, FOOT AND MOUTH DISEASE DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

4. HAND, FOOT AND MOUTH DISEASE PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS

4.1 Adimmune Corp

Beijing Minhai Biotechnology Co Ltd

Changchun Bcht Biotechnology Co Ltd

Chongging Zhifei Biological Products Co Ltd

CJ HealthCare Corp

Emergex Vaccines Ltd

Sentinext Therapeutics Sdn Bhd

Shanghai Zerun Biotechnology Co Ltd

Takeda Pharmaceutical Co Ltd

5. HAND, FOOT AND MOUTH DISEASE PIPELINE DRUG PROFILES

5.1 Current Status of Drug and Vaccine Candidates



- 5.2 Drug Snapshot
 - 5.2.1 Drug
 - 5.2.2 Mechanism of Action
 - 5.2.3 Phase
 - 5.2.4 Co-Developer
 - 5.2.5 Originator
 - 5.2.6 Synonym
 - 5.2.7 Route of Administration
 - 5.2.8 Type of Molecule
 - 5.2.9 Orphan Drug Status
 - 5.2.10 New Molecular Entity
 - 5.2.11 Area
- 5.3 Drug Details
- 5.4 Mechanism of Action
- 5.5 Licensing/Collaboration Agreements
- 5.6 Clinical Trial Details

6. HAND, FOOT AND MOUTH DISEASE PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020

7. APPENDIX

- 7.1 About the Publisher
- 7.2 Sources and Research Methodology



I would like to order

Product name: Hand, Foot and Mouth Disease R&D Pipeline Analysis Report, Q4 2020

Product link: https://marketpublishers.com/r/H74A0B1947EAEN.html

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/H74A0B1947EAEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970